The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease

Journal of Neurology

Volumn 260, Issue 11, 2013, Pages 2777-2785

  Begeti, Faye ^a,b   Tan, Adrian Y K ^a   Cummins, Gemma A ^a   Collins, Lucy M ^a   Guzman, Natalie Valle ^a   Mason, Sarah L ^a   Barker, Roger A ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Addenbrooke's Cognitive Examination; Cognition; Dementia; Huntington's disease; Screening

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; OLANZAPINE; RISPERIDONE; SULPIRIDE; TETRABENAZINE;

ADDENBROOKE COGNITIVE EXAMINATION REVISED; ADULT; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; HUNTINGTON CHOREA; LANGUAGE ABILITY; MAJOR CLINICAL STUDY; MEMORY; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PHONEMIC FLUENCY; PREDICTIVE VALUE; PRIORITY JOURNAL; SEMANTIC FLUENCY; SENSITIVITY AND SPECIFICITY; SPEECH ARTICULATION;

ADULT; ATTENTION; CASE-CONTROL STUDIES; COGNITION DISORDERS; DISABILITY EVALUATION; FEMALE; HUMANS; HUNTINGTON DISEASE; LANGUAGE; MALE; MEMORY; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; SPACE PERCEPTION;

EID: 84889571015     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7061-5     Document Type: Article

References (31)

1. Baldo JV, Schwartz S, Wilkins D, Dronkers NF (2006) Role of frontal versus temporal cortex in verbal fluency as revealed by voxel-based lesion symptom mapping. J Int Neuropsychol Soc 12:896-900
2. Bossi SR, Simpson JR, Isacson O (1993) Age dependence of striatal neuronal death caused by mitochondrial dysfunction. NeuroReport 4:73-76
3. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
4. Gleissner U, Elger CE (2001) The hippocampal contribution to verbal fluency in patients with temporal lobe epilepsy. Cortex; J Devoted Study Nerv Syst Behav 37:55-63
5. Gourovitch ML, Kirkby BS, Goldberg TE, Weinberger DR, Gold JM, Esposito G, Van Horn JD, Berman KF (2000) A comparison of rCBF patterns during letter and semantic fluency. Neuropsychology 14:353-360
6. Henry JD, Crawford JR, Phillips LH (2005) A meta-analytic review of verbal fluency deficits in Huntington's disease. Neuropsychology 19:243-252
7. Henshaw R, Jenkins BG, Schulz JB, Ferrante RJ, Kowall NW, Rosen BR, Beal MF (1994) Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res 647:161-166
8. Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA (2009) Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord 24:574-578
9. Labuschagne I, Jones R, Callaghan J, Whitehead D, Dumas EM, Say MJ, Hart EP, Justo D, Coleman A, Dar Santos RC, Frost C, Craufurd D, Tabrizi SJ, Stout JC (2013) Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease. Psychiatry Res 207:118-126
10. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004) A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65:267-277
11. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ (1998) Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 121:1329-1341
12. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW (1996) Executive and mnemonic functions in early Huntington's disease. Brain 119:1633-1645
13. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, Robbins TW, Sahakian BJ (1998) The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121:1343-1355
14. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB Jr, Siemers E, Shoulson I (2000) Rate of functional decline in Huntington's disease. Huntington study group. Neurology 54:452-458
15. Mason SL, Wijeyekoon R, Swain R, Ho AK, Smith EL, Sahakian B, Barker RA (2010) Cognitive follow up of a small cohort of Huntington's disease patients over a 5 year period. PLoS Curr 2
16. Mehta MA, Hinton EC, Montgomery AJ, Bantick RA, Grasby PM (2005) Sulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteers. J Psychopharmacol 19:29-38
17. Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, Robbins TW (2004) Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology 176:331-342
18. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW (1999) Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology 146:162-174
19. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21:1078-1085
20. Novak MJ, Tabrizi SJ (2010) Huntington's disease. BMJ 340:c3109
21. Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA (2010) Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J Neurochem 112:755-761
22. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874-880
23. Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB (2013) The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84:544-551
24. Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D (2001) Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc 7:33-44
25. Snowden JS, Craufurd D, Thompson J, Neary D (2002) Psychomotor, Executive, and Memory Function in Preclinical Huntington's Disease. J Clin Exp Neuropsychol 24:133-145
26. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791-801
27. Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC (2011) Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31-42
28. van den Bogaard S, Dumas E, Acharya T, Johnson H, Langbehn D, Scahill R, Tabrizi S, van Buchem M, van der Grond J, Roos R (2011) Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol 258:412-420
29. Walker FO (2007) Huntington's disease. Lancet 369:218-228
30. Westerink BH, Kwint HF, deVries JB (1996) The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16:2605-2611
31. Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC (2000) Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 97:2898-2903